Neurotrope Inc. appointed Ivan Gergel and Jonathan Schechter to its board.

Gergel is the managing partner and chief medical officer of New Rhein Healthcare Investors LLC, while Schechter is director of investment banking at Chardan Capital Markets.

Neurotrope is a biopharmaceutical company focused on developing a product platform for the treatment of Alzheimer's disease.